Spec market sell off is providing a compelling opportunity back in BOT with a product which works and management who aren't strangers to the FDA process or delivering massive shareholder returns.
Initially I bought BOT 12 months ago and held it all the way into the teens. It will follow a similar trajectory as we edge closer to full recruitment of Phase 2 trial results.
Near term upside from Permetrex and the new potential applications in BTX 1308: psoriasis BTX 1801: antimicrobial will re-rate us in the meantime.
Spec market sell off is providing a compelling opportunity back...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 32.5¢ | 31.5¢ | $1.940M | 6.061M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 470483 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 33000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |